Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This is an open, two-stage, phase I study to evaluate the safety, tolerability,
pharmacokinetics and preliminary efficacy of AB011 injection in patients with
CLDN18.2-positive advanced solid tumors.